Catherine A. Sabatos-Peyton

机构：Novartis (Switzerland), Novartis (China)

发表论文 70 篇 · 总被引 3381 次 · h-index 19

代表论文

• Tim-3 finds its place in the cancer immunotherapy landscape (2020 · Journal for ImmunoTherapy of Cancer · 被引 403)
• Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors (2021 · Clinical Cancer Research · 被引 369)
• Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy (2023 · Cell chemical biology · 被引 162)
• Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies (2022 · Journal for ImmunoTherapy of Cancer · 被引 162)
• Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study (2020 · Blood · 被引 70)
• Phase Ib study of sabatolimab ( MBG453 ), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes (2023 · American Journal of Hematology · 被引 54)